Cephalon Revenue and Competitors

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Cephalon's estimated annual revenue is currently $144.5M per year.(i)
  • Cephalon's estimated revenue per employee is $201,000

Employee Data

  • Cephalon has 719 Employees.(i)
  • Cephalon grew their employee count by -2% last year.

Cephalon's People

NameTitleEmail/Phone
1
VPReveal Email/Phone
2
VP Pharmacovigilance, EEA QPPVReveal Email/Phone
3
Sr. Director & Group Leader, Regulatory Medical WritingReveal Email/Phone
4
Director Regulatory CMCReveal Email/Phone
5
Director, Scientific InformationReveal Email/Phone
6
Director, Regulatory AffairsReveal Email/Phone
7
Director Global ProcurementReveal Email/Phone
8
Sr. Director and Group Leader, Regulatory AffairsReveal Email/Phone
9
Medical DirectorReveal Email/Phone
10
Clinical Research ManagerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$43.2M2156%N/AN/A
#2
$81.8M40710%N/AN/A
#3
$11.7M580%N/AN/A
#4
$1011.8M5034-9%N/AN/A
#5
$44.8M2231%N/AN/A
#6
$13.1M655%N/AN/A
#7
$16.5M8241%N/AN/A
#8
$17.3M86-5%N/AN/A
#9
$67.9M33823%N/AN/A
#10
$14.9M747%N/AN/A
Add Company

What Is Cephalon?

Follow the Teva Pharmaceuticals company page www.linkedin.com/company/teva-pharmaceuticals for information, career opportunities and the latest company updates. \r\n\r\nCephalon Inc. was established in 1987 as a global biopharmaceutical company dedicated to discovering, developing and bringing to market medications to improve the quality of life of individuals around the world. In October 2011, Cephalon was acquired by Teva Pharmaceuticals, and is now a wholly owned subsidiary. The combination of companies has enabled Teva to deliver exceptional value for patients and customers across many therapeutic areas.\r\n\r\nTeva Pharmaceutical Industries Ltd. (NYSE: TEVA) is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. \r\n\r\nHeadquartered in Israel, Teva is the world's leading generic drug maker, with a global product portfolio of more than 1,000 molecules and a direct presence in approximately 60 countries. Teva's Specialty Medicines businesses focus on CNS, respiratory oncology, pain, and women's health therapeutic areas as well as biologics. Teva currently employs approximately 45,000 people around the world and reached $20.3 billion in net revenues in 2013.

keywords:N/A

N/A

Total Funding

719

Number of Employees

$144.5M

Revenue (est)

-2%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Cephalon News

2022-04-20 - Anti Epilepsy Drugs Market Size 2022-2030| Key Players ...

Abbott Laboratories; Cephalon; Sunovion Pharmaceuticals; Bausch Health; Sanofi; Ucb Pharma; Glaxosmithkline; Johnson & Johnson; Novartis; Pfizer. Anti Epilepsy...

2022-04-20 - Nootropics Manufacturers Profiles, Market Size 2022-2029 ...

Cephalon; Purelife Bioscience; Peak Nootropics; Nootrico; SupNootropic Biological Technology; AlternaScript; Accelerated Intelligence; Onnit Labs; Powder City...

2022-04-13 - Trisenox Market Is Expected to Boom: Cephalon – Blackswan ...

Some of the Major Key players profiled in the study are Cephalon. Get PDF Sample Report + All Related Table and Graphs :.

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$165.5M7884%N/A
#2
$35M942N/AN/A
#3
$300M9880%$103.8M
#4
$303.4M12585%N/A
#5
N/A12894%N/A